Cardiac Resynchronization Therapy Reduces All-cause Mortality in Women

May 13, 2010

Media Contact

Ken Demith
Heart Rhythm Society

DENVER, May 13, 2010 – According to a sub-study of the Multicenter Automatic Defibrillator Implantation Trial-CRT (MADIT-CRT), females receive a clinically significant benefit from cardiac resynchronization therapy devices (CRT-D) compared to men. New research presented today at Heart Rhythm 2010, the Heart Rhythm Society’s 31st Annual Scientific Sessions, indicates that CRT-D therapy reduces all-cause mortality and heart failure (HF) and death end point in females, but not in males.

In MADIT-CRT patients were randomly assigned to receive CRT-D or implantable cardioverter defibrillators (ICD) therapy. A total of 1,820 patients were enrolled in 110 hospitals and a significant portion of the patient population was women (25 percent). In the results of MADIT-CRT, CRT-D was associated with a 34 percent overall reduction of death and HF in minimally symptomatic patients, yet CRT-D was more effective in women than men.

The sub-study of the MADIT-CRT study, led by Aysha Arshad, MBBS, and Arthur J. Moss, MD, sought to compare outcomes in men and women who participated in MADIT-CRT and identify the factors associated with gender differences in HF or death and all-cause mortality.

“Historically women are significantly under represented in large device trials and MADIT-CRT provides a unique study population with more than 25 percent of the patients being women,” stated Aysha Arshad, MBBS, St Luke's and Roosevelt Hospital Center and Columbia University College of Physicians and Surgeons in New York, N.Y. “The results of our research from the MADIT-CRT population show women benefit significantly more than men when it comes to CRT-D therapy.”

Results of the sub-study on MADIT-CRT found females receive a significant benefit from CRT-D therapy by reducing all-cause mortality by 72 percent. Specifically, mortality reduction was especially prominent in women with QRS duration greater than 150ms and in women with left bundle branch block (LBBB). In addition, heart failure and death end points in the female population were reduced by 69 percent, compared to only 28 percent in the male population.

According to the MADIT-CRT sub-study, CRT-D therapy proves significantly beneficial to women and the favorable results were associated with consistently greater echocardiographic evidence of reverse cardiac remodeling in female patients. Reverse cardiac remodeling can further benefit patients’ overall health and ultimately improve survival in patients with advanced heart failure.

About the Heart Rhythm Society

The Heart Rhythm Society is the international leader in science, education, and advocacy for cardiac arrhythmia professionals and patients, and the primary information resource on heart rhythm disorders. Its mission is to improve the care of patients by promoting research, education, and optimal health care policies and standards. Incorporated in 1979 and based in Washington, DC, it has a membership of more than 6,000 heart rhythm professionals in more than 72 countries around the world. For more information, visit